版本:
中国

BRIEF-Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance

March 13 Fate Therapeutics Inc-

* Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 natural killer cell cancer immunotherapy

* Fate Therapeutics -expects a first-in-human clinical trial of fate-nk100 for aml to open enrollment at masonic cancer center, university of Minnesota Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐